AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas

BMC Cancer

Table 1 Summary of AXL immunostaining in patient LPS samples

Histology	Patients (n)	Samples^c (n)	Positive for AXL immunostain
Histology	Patients (n)	Samples^c (n)	Patients (%) (n = 83)	Samples (%) (n = 104)
NF	12	12	0 (0)	0 (0)
LPS (Total)	83	104	23 (27.7)	27 (26.0)
LPS subtype
WDLPS
Extremity	3	3	-	-
Retroperitoneum	31	43	7 (22.6)	7 (16.3)
Total	34	46	7 (20.6)	7 (15.2)
DDLPS
Extremity	1	1	-	-
Retroperitoneum	17	18	4 (23.5)	4 (22.2)
Total	18	19	4 (22.2)	4 (21.1)
PLS
Extremity	23	29	10 (43.5)	11 (37.9)
Retroperitoneum	2	2	-	-
Other ^a,b	7	8	2 (28.6)	3 (37.5)
Total	31	39	12 (37.5)	14 (35.9)

^aOne patient with PLS had a primary tumor in the extremity as well as a metastatic lesion in the lung which was included on the TMA. Therefore, the total number of PLS patients is 31, not 32
^bOther locations include lung (n = 4 patients, 5 samples) and chest/back (n = 3 patients, 3 samples)
^cSeveral patients had multiple tumor samples included on the TMA

ISSN: 1471-2407